Swiss pharma giant Novartis has agreed to acquire IFM Tre from US biopharma company IFM Therapeutics in a deal worth up to $1.575bn, to add certain immunomodulatory medicines to its portfolio. IFM Tre, which was […]
Bayer, through its investment arm Leaps by Bayer, has made an investment in US-based biotechnology firm Khloris Biosciences, which is developing first-in-class anti-cancer vaccines. Specific financial details of the investment have not been divulged. Khloris […]
Silence Therapeutics has filed a clinical trial application (CTA) with the UK Medicines and Healthcare products Regulatory Agency (MHRA), seeking approval to launch a phase Ib trial for the investigational drug, SLN124. SLN124 is being […]
Merck, a leading science and technology company, has announced an investment of €150m in its manufacturing site at Aubonne, Switzerland, to expand manufacturing capacity for its biotech medicines. The investment will cover a new building […]
Roche said that ipatasertib, in combination with Tecentriq (atezolizumab) and chemotherapy, demonstrated promising anti-tumor activity in advanced triple-negative breast cancer in a Phase Ib study. The early-stage trial is assessing the safety and efficacy of […]